Replies to post #27104 on OWC Pharmaceutical Research Corp (OWCP)

[Hercules1]

OWCP:


holy smokes.


now that is what I have been talking about.


one or 2 more of these deals and we are trading around 30 cents.


this is sweet.


we will have deals like these happening for us all around the globe.


don't forget that our sublingual tablet will also net us countless deals.


OWCP is the real deal. they are making rapid progress on the ground.


it is about time some people start taking OWCP seriously.


We are head and shoulders above the rest.




***8K***

Item 1.01. Entry Into A Material Definitive Agreement.

On November 27, 2016, OWC Pharmaceutical Research Corp. (the "Registrant" or "OWCP") and its wholly-owned Israeli subsidiary, One World Cannabis Ltd (OWC Ltd") entered into a license agreement (the "License Agreement") with Emilia Cosmetics Ltd., a company organized under the laws of the State of Israel ("Emilia"), a world-leading company in the field of development, production, manufacturing and packaging of health and beauty products including for treatment of human skin disease. OWCP and OWC Ltd are sometimes referred to collectively as "OWC."

Prior to entering into the License Agreement, the Parties conducted a Development and Evaluation Program (as defined in the License Agreement) for the development of a specific product comprising Emilia's formulation with certain medical cannabis extract provided by OWC Ltd for topical treatment of Psoriasis ("OWC's Product").

Pursuant to the License Agreement, a copy of which is attached hereto as Exhibit 10.19, Emilia has granted a limited license to OWC with respect to Emilia's Licensed Intellectual Property to be developed and commercialized worldwide in the topical treatment of Psoriasis in humans with OWC's Product and upon the successful achievement of the trial, Emilia will grant OWC an exclusive, worldwide, transferable, royalty-bearing license, with the right to grant sublicenses, to use, sell and commercially exploit the Emilia Intellectual Property (the "License"). In consideration for the License, from and after the first commercial sales of the Licensed Product, OWC shall pay to Emilia a royalty at the rate of ten (10%) percent of net sales during the period of time beginning upon the first commercial sale and ending ten (10) years thereafter (the "Royalty Term"). In the event the sale of the Licensed Product during the Royalty Term reaches the minimum sales targets mutually agreed by the Parties as set forth in the License Agreement, the Royalty Term will extend to an additional five (5) year term.
The foregoing descriptions of the License Agreement are qualified in their entirety by reference to the full text of thereof, a copy of which is attached hereto as Exhibit and which is incorporated herein in its entirety by reference.

[zioni007]

That Awesome News !! This is just the beginning of a bright future for OWCP.

[Hercules1]

I just saw it.

I posted this news at Camelot already too.


I will make sure to get us some exposure at social medial outlets also.

this is a very huge deal.


and more deals like these are coming.



I have been telling the folks here to expect countless deals like these for OWCP.

[High_Profits]

**OWCP and EMILIA Cosmetics INK DEAL **

Their Clients Include
WalMart * KMart * WalGreens and TEVA !!!!

http://www.emiliac.com/company/ [ Click on Clients ] ]

Emilia Cosmetics is one of the largest manufacturers of Private Label/Contract Manufacturing health and beauty products in the world.

We offer a comprehensive outsourcing solution for the development, production and packaging of HBC products for leading retailers and brand owners globally.

Previously known as Zohar Cosmetics, our company is owned by The Emilia Development Co., a subsidiary of O. Feller Holdings Ltd.

The group holds equity stakes in companies involved in industry, infrastructure, commerce, logistics, and real estate. Emilia Cosmetics also operates a US subsidiary, Emilia Personal Care, which acts as a sales, marketing and distribution arm in the North American market, servicing most of the top 10 US retailers with National Brand Equivalent private label products.

A public company, Emilia Development is traded on the Tel Aviv Stock Exchange (EMDV). Emilia also invests and manages real estate interests in North America.

$150 Million Market Cap

[cjstocksup]

Now this is where the big $$$ can be made on Psoriasis cream.
for the development of a specific product comprising Emilia's formulation with certain medical cannabis extract provided by OWC Ltd for topical treatment of Psoriasis ("OWC's Product").

OWCP

[crazy horse 0]

This Emilia Agreement is the catalysts for OWCP

" Pursuant to the License Agreement, a copy of which is attached hereto as Exhibit 10.19, Emilia has granted a limited license to OWC with respect to Emilia's Licensed Intellectual Property to be developed and commercialized worldwide in the topical treatment of Psoriasis in humans with OWC's Product and upon the successful achievement of the trial, Emilia will grant OWC an exclusive, worldwide, transferable, royalty-bearing license, with the right to grant sublicenses, to use, sell and commercially exploit the Emilia Intellectual Property (the "License"). In consideration for the License, from and after the first commercial sales of the Licensed Product, OWC shall pay to Emilia a royalty at the rate of ten (10%) percent of net sales during the period of time beginning upon the first commercial sale and ending ten (10) years thereafter (the "Royalty Term"). In the event the sale of the Licensed Product during the Royalty Term reaches the minimum sales targets mutually agreed by the Parties as set forth in the License Agreement, the Royalty Term will extend to an additional five (5) year term."

******************************************************

*** NEW 8K OUT ***

Item 1.01. Entry Into A Material Definitive Agreement.

On November 27, 2016, OWC Pharmaceutical Research Corp. (the "Registrant" or "OWCP") and its wholly-owned Israeli subsidiary, One World Cannabis Ltd (OWC Ltd") entered into a license agreement (the "License Agreement") with Emilia Cosmetics Ltd., a company organized under the laws of the State of Israel ("Emilia"), a world-leading company in the field of development, production, manufacturing and packaging of health and beauty products including for treatment of human skin disease. OWCP and OWC Ltd are sometimes referred to collectively as "OWC."

Prior to entering into the License Agreement, the Parties conducted a Development and Evaluation Program (as defined in the License Agreement) for the development of a specific product comprising Emilia's formulation with certain medical cannabis extract provided by OWC Ltd for topical treatment of Psoriasis ("OWC's Product").

Pursuant to the License Agreement, a copy of which is attached hereto as Exhibit 10.19, Emilia has granted a limited license to OWC with respect to Emilia's Licensed Intellectual Property to be developed and commercialized worldwide in the topical treatment of Psoriasis in humans with OWC's Product and upon the successful achievement of the trial, Emilia will grant OWC an exclusive, worldwide, transferable, royalty-bearing license, with the right to grant sublicenses, to use, sell and commercially exploit the Emilia Intellectual Property (the "License"). In consideration for the License, from and after the first commercial sales of the Licensed Product, OWC shall pay to Emilia a royalty at the rate of ten (10%) percent of net sales during the period of time beginning upon the first commercial sale and ending ten (10) years thereafter (the "Royalty Term"). In the event the sale of the Licensed Product during the Royalty Term reaches the minimum sales targets mutually agreed by the Parties as set forth in the License Agreement, the Royalty Term will extend to an additional five (5) year term.
The foregoing descriptions of the License Agreement are qualified in their entirety by reference to the full text of thereof, a copy of which is attached hereto as Exhibit and which is incorporated herein in its entirety by reference.